Clinical trial

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

COMPASS PathwaysCompletedPhase 2Started Mar 1, 2019233 enrolledUnited States, Canada, Czechia, Denmark, Germany, Ireland, Netherlands, Portugal, Spain, United KingdomNCT03775200

Abstract

The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

PsilocybinDepression

Keywords

Treatment Resistant Depression

View on registry

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

This study's objects

Directly linked records, matched by DOI, trial reference, or registry, not just topic.

Publications from this trial

ArticlePsilocybin

The Relationship Between Participant Pretreatment Clinical Presentation and the Quality of Psilocybin Experience: A Retrospective Analysis.

Kirlić N, Atli M, Mistry S +2

ArticlePsilocybin

The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis.

Goodwin GM, Aaronson ST, Alvarez O +23

Related research

ArticlePsilocybin

Association of Psilocybin Use in Adolescents with Major Depressive Episode

Shah K, Trivedi C, Kamrai D +2

ArticlePsilocybin

Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.

Haridy R

ArticlePsilocybin

Cystathionine Gamma-Lyase Regulate Psilocybin Biosynthesis in <i>Gymnopilus dilepis</i> Mushroom via Amino Acid Metabolism Pathways.

Yao S, Wei C, Lin H +5